176 related articles for article (PubMed ID: 27510016)
1. Comparison of Expression Signature of Histone Deacetylases (HDACs) in Mesenchymal Stem Cells from Multiple Myeloma and Normal Donors.
Ahmadvand M; Noruzinia M; Soleimani M; Abroun S
Asian Pac J Cancer Prev; 2016; 17(7):3605-10. PubMed ID: 27510016
[TBL] [Abstract][Full Text] [Related]
2. Brazilin induces apoptosis and G2/M arrest via inactivation of histone deacetylase in multiple myeloma U266 cells.
Kim B; Kim SH; Jeong SJ; Sohn EJ; Jung JH; Lee MH; Kim SH
J Agric Food Chem; 2012 Oct; 60(39):9882-9. PubMed ID: 22967175
[TBL] [Abstract][Full Text] [Related]
3. Ginsenoside 20(s)-Rh2 as potent natural histone deacetylase inhibitors suppressing the growth of human leukemia cells.
Liu ZH; Li J; Xia J; Jiang R; Zuo GW; Li XP; Chen Y; Xiong W; Chen DL
Chem Biol Interact; 2015 Dec; 242():227-34. PubMed ID: 26482938
[TBL] [Abstract][Full Text] [Related]
4. The pan-histone deacetylase inhibitor CR2408 disrupts cell cycle progression, diminishes proliferation and causes apoptosis in multiple myeloma cells.
Baumann P; Junghanns C; Mandl-Weber S; Strobl S; Oduncu F; Schmidmaier R
Br J Haematol; 2012 Mar; 156(5):633-42. PubMed ID: 22211565
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase inhibitors in the treatment for multiple myeloma.
Hideshima T; Anderson KC
Int J Hematol; 2013 Mar; 97(3):324-32. PubMed ID: 23475757
[TBL] [Abstract][Full Text] [Related]
6. Class IIa HDAC inhibition enhances ER stress-mediated cell death in multiple myeloma.
Kikuchi S; Suzuki R; Ohguchi H; Yoshida Y; Lu D; Cottini F; Jakubikova J; Bianchi G; Harada T; Gorgun G; Tai YT; Richardson PG; Hideshima T; Anderson KC
Leukemia; 2015 Sep; 29(9):1918-27. PubMed ID: 25801913
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic therapy of cancer with histone deacetylase inhibitors.
Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
[TBL] [Abstract][Full Text] [Related]
8. Panobinostat for the treatment of multiple myeloma.
Neri P; Bahlis NJ; Lonial S
Expert Opin Investig Drugs; 2012 May; 21(5):733-47. PubMed ID: 22404247
[TBL] [Abstract][Full Text] [Related]
9. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers.
Niegisch G; Knievel J; Koch A; Hader C; Fischer U; Albers P; Schulz WA
Urol Oncol; 2013 Nov; 31(8):1770-9. PubMed ID: 22944197
[TBL] [Abstract][Full Text] [Related]
10. Anticancer activities of histone deacetylase inhibitors.
Bolden JE; Peart MJ; Johnstone RW
Nat Rev Drug Discov; 2006 Sep; 5(9):769-84. PubMed ID: 16955068
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of class II histone deacetylases in the spinal cord attenuates inflammatory hyperalgesia.
Bai G; Wei D; Zou S; Ren K; Dubner R
Mol Pain; 2010 Sep; 6():51. PubMed ID: 20822541
[TBL] [Abstract][Full Text] [Related]
12. The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells.
Golay J; Cuppini L; Leoni F; Micò C; Barbui V; Domenghini M; Lombardi L; Neri A; Barbui AM; Salvi A; Pozzi P; Porro G; Pagani P; Fossati G; Mascagni P; Introna M; Rambaldi A
Leukemia; 2007 Sep; 21(9):1892-900. PubMed ID: 17637810
[TBL] [Abstract][Full Text] [Related]
13. The tricyclic antidepressant amitriptyline inhibits D-cyclin transactivation and induces myeloma cell apoptosis by inhibiting histone deacetylases: in vitro and in silico evidence.
Mao X; Hou T; Cao B; Wang W; Li Z; Chen S; Fei M; Hurren R; Gronda M; Wu D; Trudel S; Schimmer AD
Mol Pharmacol; 2011 Apr; 79(4):672-80. PubMed ID: 21220410
[TBL] [Abstract][Full Text] [Related]
14. HDAC gene expression in pancreatic tumor cell lines following treatment with the HDAC inhibitors panobinostat (LBH589) and trichostatine (TSA).
Mehdi O; Françoise S; Sofia CL; Urs G; Kevin Z; Bernard S; Igor S; Anabela CD; Dominique L; Eric M; Ali O
Pancreatology; 2012; 12(2):146-55. PubMed ID: 22487525
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of histone deacetylase 4 increases cytotoxicity of docetaxel in gastric cancer cells.
Colarossi L; Memeo L; Colarossi C; Aiello E; Iuppa A; Espina V; Liotta L; Mueller C
Proteomics Clin Appl; 2014 Dec; 8(11-12):924-31. PubMed ID: 25091122
[TBL] [Abstract][Full Text] [Related]
16. Targeting the Interplay between HDACs and DNA Damage Repair for Myeloma Therapy.
Gkotzamanidou M; Terpou E; Kentepozidis N; Terpos E
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638744
[TBL] [Abstract][Full Text] [Related]
17. Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma.
Richardson PG; Mitsiades CS; Laubach JP; Hajek R; Spicka I; Dimopoulos MA; Moreau P; Siegel DS; Jagannath S; Anderson KC
Leuk Res; 2013 Jul; 37(7):829-37. PubMed ID: 23582718
[TBL] [Abstract][Full Text] [Related]
18. Preclinical anti-myeloma activity of the novel HDAC-inhibitor JNJ-26481585.
Stühmer T; Arts J; Chatterjee M; Borawski J; Wolff A; King P; Einsele H; Leo E; Bargou RC
Br J Haematol; 2010 May; 149(4):529-36. PubMed ID: 20331455
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylases inhibitor sodium butyrate inhibits JAK2/STAT signaling through upregulation of SOCS1 and SOCS3 mediated by HDAC8 inhibition in myeloproliferative neoplasms.
Gao SM; Chen CQ; Wang LY; Hong LL; Wu JB; Dong PH; Yu FJ
Exp Hematol; 2013 Mar; 41(3):261-70.e4. PubMed ID: 23111066
[TBL] [Abstract][Full Text] [Related]
20. Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma.
Mithraprabhu S; Kalff A; Chow A; Khong T; Spencer A
Epigenetics; 2014 Nov; 9(11):1511-20. PubMed ID: 25482492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]